secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK:        0000882796
Form:       8-K
Filed at:   2024-05-06T23:59:59+00:00
Accession:  0001171843-24-002550
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioCryst Q1 ORLADEYO revenue $88.9M (+30% YoY); 2024 guidance raised to $390-$400M
--------------------------------------------------------------------------------

- Q1 net loss narrowed to $35.4M ($0.17/sh) from $53.3M ($0.28/sh) a year ago.
- ORLADEYO net revenue grew 30% YoY to $88.9M; full-year guidance raised to $390-$400M (top end of prior range).
- Pipeline: BCX17725 (Netherton syndrome) enters clinic by end 2024; avoralstat (DME) trial planned for 2025.
- Pediatric HAE trial (APeX-P) enrollment complete; filing for label expansion to children age 2+ expected in 2025.
- Cash and investments $338.4M at Mar 31; net cash use Q1 $52.4M, expects ending 2024 cash above $300M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882796/000117184324002550/0001171843-24-002550-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882796/000117184324002550/f8k_050624.htm
  HTML page:      https://secwatch.observer/filing/0001171843-24-002550

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer